ProShares Ultra Nasdaq Biotechnology (BIB)
| Assets | $63.17M |
| Expense Ratio | 0.95% |
| PE Ratio | n/a |
| Shares Out | 1.23M |
| Dividend (ttm) | $0.50 |
| Dividend Yield | 0.96% |
| Ex-Dividend Date | Sep 25, 2024 |
| Payout Ratio | n/a |
| 1-Year Return | -5.22% |
| Volume | 6,998 |
| Open | 49.49 |
| Previous Close | 50.50 |
| Day's Range | 49.49 - 52.41 |
| 52-Week Low | 47.20 |
| 52-Week High | 69.56 |
| Beta | 1.34 |
| Holdings | 223 |
| Inception Date | Apr 8, 2010 |
About BIB
Fund Home PageThe ProShares Ultra Nasdaq Biotechnology (BIB) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index. The fund provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ. BIB was launched on Apr 8, 2010 and is issued by ProShares.
Top 10 Holdings
68.07% of assets| Name | Symbol | Weight |
|---|---|---|
| Cte ? Proshares Trust M | n/a | 15.95% |
| United States Treasury Bills 0% | B 0 04.01.25 | 15.62% |
| Gilead Sciences, Inc. | GILD | 8.05% |
| Vertex Pharmaceuticals Incorporated | VRTX | 6.33% |
| Amgen Inc. | AMGN | 5.43% |
| Cash | n/a | 4.86% |
| Regeneron Pharmaceuticals, Inc. | REGN | 4.23% |
| AstraZeneca PLC | AZN | 3.20% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.59% |
| Biogen Inc. | BIIB | 1.82% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 25, 2024 | $0.153 | Oct 2, 2024 |
| Jun 26, 2024 | $0.265 | Jul 3, 2024 |
| Mar 20, 2024 | $0.040 | Mar 27, 2024 |
| Dec 20, 2023 | $0.038 | Dec 28, 2023 |
| Dec 22, 2022 | $0.020 | Dec 30, 2022 |
| Sep 21, 2010 | $0.011 | Sep 28, 2010 |
News
Will The Next Batch Of Tech Earnings Encourage Investors To Rotate Back In?
All eyes will remain on big tech this week with Microsoft, Amazon, Meta, and Apple set to report for Q2. Outlier earnings this week include - McDonald's & Boeing. During this second peak week of the Q...
Equity CEFs/ETFs: Top Picks For 2024 - Part II
In Part I of my Top Picks For 2024, I explained why we saw such extreme valuation losses in most equity CEFs in 2023 and what that could-mean for 2024. In my opinion, liquidity was the over-riding fac...
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...